Advances in immunotherapy for cervical cancer

por Grau-Bejar, Juan Francisco, Garcia-Duran, Carmen, Garcia-Illescas, David, Mirallas, Oriol, Oaknin, Ana
Publicado 2023

Real‐World Delivery of Rucaparib to Patients with Ovarian Cancer: Recommendations Based on an Integrated Safety Analysis of ARIEL2 and Study 10

por Drew, Yvette, Kristeleit, Rebecca S., Oaknin, Ana, Ray‐Coquard, Isabelle, Haris, Noor Md., Swisher, Elizabeth M.
Publicado 2019

The Changing Landscape of Systemic Treatment for Cervical Cancer: Rationale for Inhibition of the TGF-β and PD-L1 Pathways

por Birrer, Michael J., Fujiwara, Keiichi, Oaknin, Ana, Randall, Leslie, Ojalvo, Laureen S., Valencia, Christian, Ray-Coquard, Isabelle
Publicado 2022

First-line PARP inhibitors in ovarian cancer: summary of an ESMO Open - Cancer Horizons round-table discussion

por Banerjee, Susana, Gonzalez-Martin, Antonio, Harter, Philipp, Lorusso, Domenica, Moore, Kathleen N, Oaknin, Ana, Ray-Coquard, Isabelle
Publicado 2020

Characterization and Management of Adverse Reactions in Patients with Advanced Endometrial Carcinoma Treated with Lenvatinib Plus Pembrolizumab

por Makker, Vicky, Taylor, Matthew H., Oaknin, Ana, Casado Herraez, Antonio, Orlowski, Robert, Dutta, Lea, Ren, Min, Zale, Melissa, O'Malley, David M.
Publicado 2021

Genomic heterogeneity and efficacy of PI3K pathway inhibitors in patients with gynaecological cancer

por Rodriguez-Freixinos, Victor, Ruiz-Pace, Fiorella, Fariñas-Madrid, Lorena, Garrido-Castro, Ana Christina, Villacampa, Guillermo, Nuciforo, Paolo, Vivancos, Ana, Dienstmann, Rodrigo, Oaknin, Ana
Publicado 2019

A phase I dose-finding, pharmacokinetics and genotyping study of olaparib and lurbinectedin in patients with advanced solid tumors

por Poveda, Andres, Oaknin, Ana, Romero, Ignacio, Guerrero-Zotano, Angel, Fariñas-Madrid, Lorena, Rodriguez-Freixinos, Victor, Mallol, Pedro, Lopez-Reig, Raquel, Lopez-Guerrero, Jose Antonio
Publicado 2021

Management of advanced ovarian cancer in Spain: an expert Delphi consensus

por Redondo, Andres, Oaknin, Ana, Rubio, Maria Jesus, Barretina-Ginesta, Maria-Pilar, de Juan, Ana, Manso, Luis, Romero, Ignacio, Martin-Lorente, Cristina, Poveda, Andres, Gonzalez-Martin, Antonio
Publicado 2021

Clinical Activity and Safety of the Anti–Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair–Deficient Endometrial Cancer: A...

por Oaknin, Ana, Tinker, Anna V., Gilbert, Lucy, Samouëlian, Vanessa, Mathews, Cara, Brown, Jubilee, Barretina-Ginesta, Maria-Pilar, Moreno, Victor, Gravina, Adriano, Abdeddaim, Cyril, Banerjee, Susana, Guo, Wei, Danaee, Hadi, Im, Ellie, Sabatier, Renaud
Publicado 2020

Phase 2 Trial (POLA Study) of Lurbinectedin plus Olaparib in Patients with Advanced Solid Tumors: Results of Efficacy, Tolerability, and the Translational Study

por Poveda, Andres, Lopez-Reig, Raquel, Oaknin, Ana, Redondo, Andres, Rubio, Maria Jesus, Guerra, Eva, Fariñas-Madrid, Lorena, Gallego, Alejandro, Rodriguez-Freixinos, Victor, Fernandez-Serra, Antonio, Juan, Oscar, Romero, Ignacio, Lopez-Guerrero, Jose A.
Publicado 2022

Final survival analysis of topotecan and paclitaxel for first-line treatment of advanced cervical cancer: An NRG oncology randomized study

por Tewari, Krishnansu S., Sill, Michael W., Birrer, Michael J., Penson, Richard T., Huang, Helen, Moore, David H., Ramondetta, Lois M., Landrum, Lisa M., Oaknin, Ana, Reid, Thomas J., Leitao, Mario M., Michael, Helen E., Monk, Bradley J.
Publicado 2023

Relacorilant + Nab-Paclitaxel in Patients With Recurrent, Platinum-Resistant Ovarian Cancer: A Three-Arm, Randomized, Controlled, Open-Label Phase II Study

por Colombo, Nicoletta, Van Gorp, Toon, Matulonis, Ursula A., Oaknin, Ana, Grisham, Rachel N., Fleming, Gini F., Olawaiye, Alexander B., Nguyen, Dorothy D., Greenstein, Andrew E., Custodio, Joseph M., Pashova, Hristina I., Tudor, Iulia C., Lorusso, Domenica
Publicado 2023

Lurbinectedin in patients with pretreated endometrial cancer: results from a phase 2 basket clinical trial and exploratory translational study

por Kristeleit, Rebecca, Leary, Alexandra, Delord, Jean Pierre, Moreno, Victor, Oaknin, Ana, Castellano, Daniel, Shappiro, Geoffrey I., Fernández, Cristian, Kahatt, Carmen, Alfaro, Vicente, Siguero, Mariano, Rueda, Daniel, Zeaiter, Ali, Awada, Ahmad, Santaballa, Ana, Zaman, Khalil, Sehouli, Jalid, Subbiah, Vivek
Publicado 2023

Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study

por Matulonis, Ursula A., Lorusso, Domenica, Oaknin, Ana, Pignata, Sandro, Dean, Andrew, Denys, Hannelore, Colombo, Nicoletta, Van Gorp, Toon, Konner, Jason A., Marin, Margarita Romeo, Harter, Philipp, Murphy, Conleth G., Wang, Jiuzhou, Noble, Elizabeth, Esteves, Brooke, Method, Michael, Coleman, Robert L.
Publicado 2023

Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer

por Makker, Vicky, Taylor, Matthew H., Aghajanian, Carol, Oaknin, Ana, Mier, James, Cohn, Allen L., Romeo, Margarita, Bratos, Raquel, Brose, Marcia S., DiSimone, Christopher, Messing, Mark, Stepan, Daniel E., Dutcus, Corina E., Wu, Jane, Schmidt, Emmett V., Orlowski, Robert, Sachdev, Pallavi, Shumaker, Robert, Casado Herraez, Antonio
Publicado 2020

Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study

por Oaknin, Ana, Pothuri, Bhavana, Gilbert, Lucy, Sabatier, Renaud, Brown, Jubilee, Ghamande, Sharad, Mathews, Cara, O'Malley, David M., Kristeleit, Rebecca, Boni, Valentina, Gravina, Adriano, Banerjee, Susana, Miller, Rowan, Pikiel, Joanna, Mirza, Mansoor R., Dewal, Ninad, Antony, Grace, Dong, Yuping, Zografos, Eleftherios, Veneris, Jennifer, Tinker, Anna V.
Publicado 2023

Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial

por Colombo, Nicoletta, Moore, Kathleen, Scambia, Giovanni, Oaknin, Ana, Friedlander, Michael, Lisyanskaya, Alla, Floquet, Anne, Leary, Alexandra, Sonke, Gabe S., Gourley, Charlie, Banerjee, Susana, Oza, Amit, González-Martín, Antonio, Aghajanian, Carol, Bradley, William H., Kim, Jae-Weon, Mathews, Cara, Liu, Joyce, Lowe, Elizabeth S., Bloomfield, Ralph, DiSilvestro, Paul
Publicado 2021

Safety and activity of anti-mesothelin antibody–drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multice...

por Santin, Alessandro D, Vergote, Ignace, González-Martín, Antonio, Moore, Kathleen, Oaknin, Ana, Romero, Ignacio, Diab, Sami, Copeland, Larry J, Monk, Bradley J, Coleman, Robert L, Herzog, Thomas J, Siegel, Jonathan, Kasten, Linda, Schlicker, Andreas, Schulz, Anke, Köchert, Karl, Walter, Annette O, Childs, Barrett H, Elbi, Cem, Bulat, Iurie
Publicado 2023

Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial

por Naumann, R. Wendel, Hollebecque, Antoine, Meyer, Tim, Devlin, Michael-John, Oaknin, Ana, Kerger, Joseph, López-Picazo, Jose M., Machiels, Jean-Pascal, Delord, Jean-Pierre, Evans, Thomas R.J., Boni, Valentina, Calvo, Emiliano, Topalian, Suzanne L., Chen, Tian, Soumaoro, Ibrahima, Li, Bin, Gu, Junchen, Zwirtes, Ricardo, Moore, Kathleen N.
Publicado 2019

SMARCA4 deficient tumours are vulnerable to KDM6A/UTX and KDM6B/JMJD3 blockade

por Romero, Octavio A., Vilarrubi, Andrea, Alburquerque-Bejar, Juan J., Gomez, Antonio, Andrades, Alvaro, Trastulli, Deborah, Pros, Eva, Setien, Fernando, Verdura, Sara, Farré, Lourdes, Martín-Tejera, Juan F., Llabata, Paula, Oaknin, Ana, Saigi, Maria, Piulats, Josep M., Matias-Guiu, Xavier, Medina, Pedro P., Vidal, August, Villanueva, Alberto, Sanchez-Cespedes, Montse
Publicado 2021